Therapy Offers Expanded in the European ARMD/DME/RVO Market in the Last Quarter of 2025  

STADA announced Afiveg’s European approval, its second ophthalmology biosimilar.

Sandoz announced Afqlir’s European launch as an affordable biosimilar for major retinal diseases.

Teva and Horus Pharma initiated a strategic partnership with Formycon to commercialize Ahzantive and Baiama, following their respective approvals.

Novartis introduced the “Windshield” DTC unbranded campaign.

Biogen announced a positive CHMP opinion for Byooviz’s pre-filled syringe, alongside Opuviz’s launch, depending on patent expirations.

Bayer featured Eylea 8 mg’s treatment interval extensions of up to six months.

Horus Pharma promoted Iluvien for chronic DME that was insufficiently responsive to other treatments.

Roche promoted Vabysmo’s treat-and-extend dosing schedule of up to 16 weeks and early diagnosis to improve outcomes in nAMD and DME.